Research and Markets - Botulinum Toxin Market 2015-2022 - Global Strategic Business Report 2016: Leading Players are Allergan, Ipsen, Medy-Tox, Merz Pharma, Metabiologics, Revance Therapeutics & US WorldMeds

News provided by

Oct 25, 2016, 05:10 ET

DUBLIN, October 25, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 15 companies including many key and niche players such as

Allergan Plc (Ireland)
Ipsen Group (France)
Medy-Tox Inc. (South Korea)
Merz Pharma GmbH & Co. KGaA (Germany)
Metabiologics, Inc. (US)
Revance Therapeutics, Inc. (US)
US WorldMeds (US)

Key Topics Covered:

1. INDUSTRY OVERVIEW

Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth
Developed Regions Dominate Botulinum Toxin Market
Developing Markets to Drive Future Growth
Cosmetic BTX
A Promising Application Market
Factors Propelling the Cosmetic BT Market
In a Nut Shell
Rise in the Number of Musculoskeletal Indications
An Opportunity Indicator
Pharma Companies Keenly Eye Lucrative BT Market

2. COMPETITIVE LANDSCAPE

Allergan Leads the Global BTX Market
Botulinum Toxin Products Worldwide
Botox
The Leading Brand in Cosmetic BTX Market
Biosimilar BTX Variants Challenge Botox's Leadership
Discontinuation of PurTox Averts Competition to Botox®
Lack of Differentiation among Approved BTX Products
Comparison of Leading Neurotoxins
Botox, Dysport and Xeomin by Safety and Efficacy
Revance Therapeutics: All Hopes on Topical Botox Formulation
Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario
A Review of Major BTX Products

3. MARKET TRENDS & ISSUES

Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market
Botulinum Toxin
The Preferred Solution in Facial Injectables Market
Growing Acceptance of Cosmetic BTX Treatments Favors Market Growth
Rising Disposable Incomes Propel Sales
Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
Urgent Need for Physician Education about Off-Label Usage
High Voltage Ad Campaigns Boost Patient Awareness
Digital Revolution to Impact Consumer Choices
Financing of Non-Reimbursed Healthcare: Need of the Hour
Combination Therapies: A Double Whammy Success

4. PRODUCT OVERVIEW

Botulinum Toxin: A Poison That Cures
Structure & Mechanism of Action
Disadvantages
Classification of Botulinum Toxin
Botulinum Toxin Type A
Historical Timeline of Botulinum Toxin: 1885-2002
Key Cosmetic Indications for Botulinum Toxin
Site of Injection and Doses of Neurotoxins used in the Treatment of Dystonias
Chronic Pain
Botox in Migraine Treatment
Hyperhidrosis
Bladder Dysfunctions
Spasticity
Other Applications
Side Effects
An Overview of Side Effects of BTX Treatment

5. RESEARCH BREAKTHROUGHS IN THE RECENT PAST

University of Kansas Researchers Study Botulinum ToxinA Role in Minimally Invasive Treatment of Neurogenic Bladder
Researchers at Baylor College of Medicine Revealed Use of Botox Injections for Treatment of Filamentary Keratitis
Researchers at Medical School of Hannover and Sanford-Burnham Medical Research Institute Study Effect of the Hostile Human Stomach Environment on BT
Investigators Prove Role of BTX A for Treatment of Achalasia
Researchers at University of Freiburg Conduct New Studies on Salmonella
Researchers at Monash University Use Botox to Resolve Asthma Wrinkles

6. PRODUCT INTRODUCTIONS/APPROVALS

Galderma Initiates Phase II Clinical Trial on Botulinum Toxin
Daewoong Unveils Nabota Botulinum Toxin-Type Formula
Medy-TOX Submits Patent Application for Lyophilized Botulinum Toxin
Botox Receives Approval for Treatment of Ankle Disability in the UK
Anterios Develops AI-09 Next-Generation Injectable Botulinum Product
Ipsen Receives Health Canada Approval for Dysport®
Eisai Announces Plans to Launch Nerbloc® in Japan
Cangene Receives FDA Approval for Botulism Antitoxin
Allergan Receives FDA Approval for BOTOX® for the Treatment of Crow's Feet Lines in Adults

7. RECENT INDUSTRY ACTIVITY

Allergan Gains Marketing Approval for BOTOX Vista® in Japan
Allergan Takes Over Anterios
FDA Approves BOTOX® for Treatment of Adult Lower Limb Spasticity
Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug Candidate
Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins
Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel
Bloomage BioTechnology and Medytox to Establish JV in China
Ipsen Gains FDA's sBLA Approval for Dysport®
Actavis Bags FDA Approval for Expanding BOTOX® Label
Actavis Acquires Allergan